SecBot SecBot

TENX drug pipeline

TENAX THERAPEUTICS, INC. · 1 rated drug
$1.48
−8.6% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
1
1 bullish
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
▲ bullish
Impact
PhasePhase 3
Time to marketIf LEVEL Phase 3 data is positive (Aug 2026), Tenax would need to complete a second registrational study (LEVEL-2) and file an NDA. Realistic best-case US approval would be 2028-2029, assuming positive results and a standard FDA review cycle.

levosimendan Updated Jul 2

What to watch

The Phase 3 LEVEL topline readout in August 2026 is a make-or-break binary catalyst. Positive data could unlock a ~$2B+ market opportunity as the first approved therapy for PH-HFpEF, while a miss would likely devastate the stock. With a strong cash runway (~$118.8M through Q1 2028), no near-term dilution risk exists. This is a pure binary options-style biotech setup, size accordingly.

Bull case
  • PH-HFpEF is a large, underserved market with zero FDA-approved therapies, oral levosimendan could be first-to-market if LEVEL succeeds.
  • Phase 2 data showed IV levosimendan produced statistically significant improvements in exercise hemodynamics and 6-minute walk distance in PH-HFpEF patients, de-risking the mechanism.
  • IV levosimendan is already approved in 60+ countries for related indications, providing a strong safety database and known tolerability profile.
Bear case
  • The LEVEL Phase 3 readout is a binary event, failure would likely destroy the stock, as Tenax is effectively a single-asset company.
  • The $100M private placement at $3/share in Aug 2024 was massively dilutive (priced at a fraction of current levels), and warrant overhang could pressure the stock.
  • Competition from SGLT2 inhibitors (Farxiga, Jardiance) is expanding across HFpEF indications, potentially narrowing levosimendan's differentiation.

Clinical trials

1 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
levosimendanOpen-Label Rollover Study of Levosimendan in PH-HFpEF PatientsPhase 2Completed · results35Apr 25, 2023